Instructions for Limenda (metronidazole, miconazole) vaginal suppositories
English Product Name Limenda
Limenda
Release Form
750 mg+200 mg vaginal soup: 7 or 14 pcs. packed with fingerstrappers (7 or 14 pcs.)
Description
Vaginal suppositories are white with a yellowish or yellowish-greenish tinge of color and torpedo-shaped, smooth on a longitudinal section, without spots.
1 soup.
metronidazole 750 mg
miconazole nitrate 200 mg
[PRING] Vitesol S55 - 1550 mg.
7 pcs. - blisters (1) complete with fingerprint package (7 pcs.) - cardboard packs.
7 pcs. - blisters (2) complete with fingerprint package (14 pcs.) - cardboard packs.
ATX codes
G01AF20 Combinations of imidazole derivatives
Active ingredient
- metronidazole
- miconazole nitrate
Pharmacotherapeutic group Limenda
Antimicrobial combination agent (antimicrobial and antifungal agent + antifungal agent)
Retention conditions
The preparation should be stored in the original package (pack), in a place inaccessible to children at a temperature not exceeding twenty-five °C.
Expiration date
The shelf life is three years. Do not apply after expiry date.
Pharmacological effect Limenda
The inventive limenda is embodied in the form of a combined agent exhibiting antiprotozoan, antifungal and antibacterial activity. Its composition includes metronidazole and miconazole.
Pharmacodynamics Limenda
Metronidazole is a 5-nitroimidazole and has a bactericidal effect, exhibiting specific activity to the DNA of microorganisms.
Its action is based on the biochemical reduction of the 5-nitrogroup using intracellular transport proteins of anaerobes and protozoa. The restored 5-nitrogroup binds to the DNA of the microorganisms, which inhibits their nucleic acid synthesis and ultimately kills the bacteria. Metronidazole is highly effective against Trichomonas vaginalis, Gardnerella vaginalis, Giardia intestinalis, Entamoeba histolytica, Lamblia spp., and obligate anaerobes Bacteroides spp., including Bacteroides fragilis and others, Fusobacterium spp., Veillonella spp., Prevotella spp., and some gram-positive bacteria (eg, Eubacterium spp., Clostridium spp.).
Method of use, course and dosage Limenda
It is given intravaginally with one vaginal suppository at bedtime for seven days.
For recurrent vaginitis or vaginitis refractory to other treatments, Limenda should be given for fourteen days.
Vaginal suppositories should be inserted deep into the vagina using disposable fingerlings enclosed in a package.
For older patients over 65 years of age, dosing adjustments are not required.
Testimony Limenda
Metronidazole
Suction and distribution
When used topically, metronidazole penetrates the bloodstream. The maximum concentration (Cmax) in blood occurs 6 to 12 hours later and is about 50% of the Cmax attained (1 to 3 hours later) after a single oral dose of an equivalent dose.
Plasma protein binding is less than 20%. The drug penetrates into breast milk, as well as various tissues, passing through blood-brain and placental barriers.
Metabolism and eliminationMetronidazole is metabolized in the liver through hydroxylation, oxidation, and glucuronization. The activity of the major metabolite (2-oxymetronidazole) accounts for about 30% of the activity of the original substance.
About 60 to 80% of the dose is eliminated by the kidneys, 20% of which remain unchanged. Metronidazole's metabolite gives urine a red-brown hue due to its metabolic water-soluble pigment. About 6 to 15% are excreted through the intestine.
Myconazole
Systemic absorption of myconazole is low after intravaginal use. It is rapidly metabolized in the liver and has difficulty overcoming histohemic barriers. After 8 hours, 90% of the myconazole remains in the vagina, and the unchanged drug does not enter plasma or urine.
- Nosology Limenda (ICD codes)
- A59
- Trichomoniasis
- B37.3
- Candidiasis of vulva and vagina
- N76
- Other inflammatory diseases of vagina and vulva
- N77.1
- Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
- N89.8
- Other noninflammatory diseases of vagina
